Healthy
Conditions
Keywords
lumiVida™, cognition, mood, sleep, tryptophane
Brief summary
The purpose of this study is to determine whether a chronic dose of a tryptophan-rich protein drink (lumiVida™) can improve cognitive function, emotional processing and sleep in middle-aged women. In addition, also genetic predictors of susceptibility to an increase of Trp levels will be investigated. lumiVida™ is considered a dietary supplement, and therefore it is not an approved drug by the Food and Drug Administration (FDA). It is regulated like a food. The U.S. Food and Drug Administration does not strictly regulate herbs and dietary supplements. The investigators do not claim that this supplement is meant to treat any ailment
Detailed description
The treatment conditions are either placebo or lumiVida™ (N=30 per group) 0.5 g twice a day (total 1 g/ day). The first testing took place on the screening day (baseline). Subsequently, participants were supplied with supplements for 19 days intervention (sachets which had to be dissolved in 200-ml water). After 19 days, participants were tested again (same tests as on the baseline day). An additional facet was the completion of a 'sleep diary', which asks questions about sleep quality and latency, and bed-time mood, as well as allowing recording of timing of supplement taking.
Interventions
DIETARY_SUPPLEMENTlumiVida™
DIETARY_SUPPLEMENTPlacebo
Sponsors
DSM Nutritional Products, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Physically and mentally healthy (defined by not concurrently receiving medical/pharmacological treatment (except mild painkillers), free of gastrointestinal complaints, not in pain, not diagnosed with a psychiatric disorder * Female * Aged: 45 - 65 years
Exclusion criteria
* Having received treatment in the last 12 months for: depression, anxiety, neurological disease including migraine, dementia, epilepsy, Parkinson's. * History of any psychiatric or neurological illness in the last 2 years. * Current medication targeting the brain (except mild painkillers, e.g. pure paracetamol, ibuprofen), including steroids, e.g. for contraception, Hormone Replacement Therapy (HRT), drugs for weight control, stimulants (e.g. phenylephrine, ephedrine), antihistamines, and some herbal or nutritional remedies including St. John's Wort, 5-hydroxy-tryptophan, or melatonin (which can affect the serotonin system). * Pregnancy * Current gastrointestinal complaints * Diabetes (Type 1 or 2) * Body mass index \< 18 or \> 35
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in Driving Hazard Perception Test at day 19 | Day 1 (baseline) and day 19 | Measurement of participant's ability to perceive accurately and react to potential hazards whilst driving: this will be measured by computer software that displays a video recording from the driver's perspective through the windscreen of a moving car. |
| Change from baseline in Affective Go/No-Go at day 19 | Day 1 (baseline) and day 19 | Assessment of information processing biases for positive and negative stimuli |
| Change from baseline in Emotion Recognition Task at day 19 | Day 1 (baseline) and day 19 | Assessment of relatively enhanced recognition of positive emotional facial expressions on morphed photographs |
| Change from baseline in measures of mood (MAPS scale) at day 19 | Day1 (baseline) and day 19 | Computer-based series of 9-point ratings scales to measure mood |
| Change from baseline in sleep diaries until day 19 | Day 1 and 2 prior treatment (baseline) and at day 1, 2, 4, 5, 11, 12, 18 and 19 of intake period | Sleep diaries: Questions about sleep quality and latency, bed-time mood and alertness aspects. |
| Change from baseline in Simple Reaction Time (SRT) at day 19 | Day 1 (baseline) and day 19 | Measurement of reaction time and sustained attention |
| Change from baseline in the Rotary Pursuit Task at day 19 | Day 1 (baseline) and day 19 | Measurement of psychomotor coordination and motor learning |
| Change from baseline in Verbal Recognition Memory test (VRM) at day 19 | Day 1 (baseline) and day 19 | Recognition of words out of a list of words they have seen before |
| Change from baseline in Match To Sample Visual search (MTS) at day 19 | Day 1 (baseline) and day 19 | Measurement of visual attention, and speed and accuracy of responding |
| Change from baseline in Rapid Visual Information Processing task (RVIP) at day 19 | Day 1 (baseline) and at day 19 | Assessment of sustained attention and working memory |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in plasma TRP/LNAA ratio at day 19 | Day 1 (baseline) and day 19 | Measurement of L-tryptophan (TRP) and large neutral amino acids (LNAA) amino acids in blood samples (plasma) |
| Genetic evaluation of genotypes of the serotonin transporter protein (5HTTP) | Baseline | Buccal (cheek) cell assays for DNA extraction for 5HTTP polymorphism analysis |
Countries
United Kingdom
Outcome results
None listed